Alligator Bioscience starts clinical phase I study with ATOR-1015
A first-in-class bispecific CTLA-4 antibody Lund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announ ...
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cance ...
Alligator Bioscience to receive million-dollar payments – AbClon partner exercises option
Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than U ...
Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144 Lund, Sweden, October 30, 2018 – Alligator Bi ...
New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017
Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...